证券代码：002437 证券简称：誉衡药业 哈尔滨誉衡药业股份有限公司投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |-----------------------|--------------------------|--------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活 | □ | 媒体采访 □业绩说明会 | | 动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | 参与单位名称 | 兴业证券项军、孙晓东 | | | 及人员姓名 | | | | | | | | 时间 | 2015 年 1 月 25 | 日上午 10：30 | | 上市公司接待 人员姓名 | 杨海峰，财务总监刁秀强。 | 总经理杨红冰，副总经理、董秘国磊峰，副总经理赵艳萍、毛嘉农、 | | 投资者关系活 | | 一、副总经理、董秘国磊峰，总经理杨红冰介绍停牌期间的重要工 | | 动主要内容介 | 作。 | | | 绍 | （一）非公开发行 ...

证券代码：002437 证券简称：誉衡药业 哈尔滨誉衡药业股份有限公司投资者关系活动记录表 编号：2016-002 | --- | --- | --- | |-------------------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系活 | □ | 媒体采访 □业绩说明会 | | 动类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | 参与单位名称 及人员姓名 | | 中国建设银行（伦敦）有限公司投资银行部总经理衞丹、威灵顿管理香港有限公司 高级董事总经理马德高、威灵顿管理香港有限公司全球股票投资组合管理鞠淳起 | | 时间 | 2016 年 9 月 6 | 日上午 10:30-11:30 | ...

证券代码：002437 证券简称：誉衡药业 哈尔滨誉衡药业股份有限公司投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |---------------------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系活 | □ | 媒体采访 □业绩说明会 | | 动类别 | □ □ 现场参观 | 新闻发布会 □路演活动 | | 参与单位名称 及人员姓名 | Investment Management | 国泰证券黄议玱、叶岦升，复华投信杨佳升，群益投信 ...

证券代码：002437 证券简称：誉衡药业 哈尔滨誉衡药业股份有限公司投资者关系活动记录表 编号：2016-003 | --- | --- | --- | |-----------------------------|------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2022-032 哈尔滨誉衡药业股份有限公司 关于参加"2022年投资者网上集体接待日活动暨业绩说明会"的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，黑龙江省上市公司协会联 合深圳市全景网络有限公司，将于 2022 年 5 月 12 日 14:30-16:30 在"全景路演" （https://rs.p5w.net/html/132395.shtml）举办"黑龙江省上市公司 2022 年投资者 网上集体接待日活动暨业绩说明会"。 哈尔滨誉衡药业股份有限公司（以下简称"公司"）出席本次活动人员有： 公司董事、总经理刁秀强先生，公司董事、副总经理、财务总监纪作哲先生，公 司副总经理、董事会秘书刘月寅女士。 为充分尊重投资者、提升交流的针对性，现就公司本次活动提前向投资者公 开征集问题，广泛听取投资者的意见和建议。投资者可于 2022 年 5 月 12 日 12 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2020-105 哈尔滨誉衡药业股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨誉衡药业股份有限公司（以下简 称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络有限公司共同举 办的"黑龙江省上市公司 2020 年度投资者网上集体接待日"活动，现将有关事 项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）参与公司本次 投资者集体接待日活动，时间为 2020 年 11 月 12 日 14:00 至 16:30。 届时公司财务副总监兼总经理助理纪作哲先生将通过网络在线问答互动的 形式，与投资者就公司治理、发展经营情况、融资情况和可持续发展等投资者关 注的问题进行交流。期间，公司高管将全程在线，实时回答投资者的提问。 欢迎广大投资者积极参与。 特此公告。 哈尔滨誉衡药业股份有限公司 董 ...

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 2,734,204,476.88, representing a 7.77% increase compared to CNY 2,537,094,408.10 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 232,281,100.76, up by 2.81% from CNY 225,936,011.68 in the previous year[18]. - The net cash flow from operating activities was CNY 437,180,511.99, reflecting an 8.20% increase from CNY 404,061,781.12 in the same period last year[18]. - The basic earnings per share for the reporting period was CNY 0.1057, a 2.82% increase compared to CNY 0.1028 in the previous year[18]. - Total assets at the end of the reporting period were CNY 9,537,805,452.70, a 0.64% increase from CNY 9,477,173,262.97 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company increased by 4.91% to CNY 4,536,176,411.46 from CNY 4,324,011,225.63 at the end of the previous year[18]. - The company achieved operating revenue of 2.734 billion RMB, a year-on-year increase of 7.77%[42]. - Net profit attributable to shareholders reached 232 million RMB, up 2.81% compared to the same period last year[36]. - Operating cash flow net amount was 437 million RMB, reflecting an 8.20% increase year-on-year[42]. - The total revenue for the reporting period reached ¥2,734,204,476.88, representing a year-on-year increase of 7.77% compared to ¥2,537,094,408.10 in the same period last year[44]. Assets and Liabilities - Cash and cash equivalents increased by 229.57% to approximately 174 million RMB, influenced by the combined effects of operating, investing, and financing activities[42]. - Total assets increased to CNY 9,537,805,452.70 from CNY 9,477,173,262.97, reflecting a growth of 0.64%[114]. - Current liabilities rose to CNY 4,366,099,310.01 from CNY 4,017,634,432.94, an increase of 8.67%[115]. - Non-current liabilities decreased significantly from CNY 1,065,728,802.08 to CNY 563,558,192.93, a reduction of 47.10%[116]. - Total liabilities decreased to CNY 4,929,657,502.94 from CNY 5,083,363,235.02, a decline of 3.02%[116]. - Owner's equity increased to CNY 4,608,147,949.76 from CNY 4,393,810,027.95, representing a growth of 4.87%[116]. Revenue Sources - The pharmaceutical manufacturing segment generated ¥2,231,405,368.34, accounting for 81.61% of total revenue, with an 8.39% increase from the previous year[44]. - Sales contribution from chronic disease oral products exceeded 50%, with significant growth in specific products: calcium zinc gluconate oral solution increased over 17% and potassium chloride sustained-release tablets grew over 40%[37]. - Domestic sales accounted for 99.88% of total revenue, amounting to ¥2,730,961,421.27, with a growth of 7.75% year-on-year[44]. Research and Development - Research and development investment decreased by 35.93% to approximately 56 million RMB, primarily due to the exclusion of certain biopharmaceutical R&D costs from consolidation[42]. - The company is advancing clinical research for its PD-1 monoclonal antibody, aiming for product registration application within the year and has enrolled over 300 safety evaluation subjects[38]. Market Strategy and Competitiveness - The company aims to strengthen its core competitiveness by focusing on "products, customers, and sales teams" while expanding its market reach[33]. - The company has established a sales network through acquisitions and partnerships, enhancing its market presence and competitiveness[32]. - The marketing strategy focuses on "integrating resources and sinking to the terminal," leading to stable growth in contributions from secondary hospitals and county-level markets[39]. Risks and Challenges - The company faced risks and has outlined measures to address them in the report[5]. - The company faces industry policy risks that may lead to a decline in product sales due to ongoing regulatory changes in the healthcare sector[55]. - There is a risk of goodwill impairment due to multiple acquisitions, which could impact the company's financial performance if the acquired companies do not meet expected earnings[56]. - The company is committed to managing drug development risks by closely following clinical trial policies and implementing effective risk mitigation strategies[57]. - The company emphasizes strict adherence to operational standards to mitigate production and operational risks related to product quality and safety[58]. Shareholder Information - The total number of shares is 2,198,122,950, with 98.94% being unrestricted shares[91]. - The number of restricted shares decreased by 2,739,394 during the reporting period, resulting in a total of 8,423,738 restricted shares at the end of the period[94]. - Harbin Yuheng Group Co., Ltd. held 42.30% of shares, totaling 929,789,325 shares, which are frozen[97]. - YU HENG INTERNATIONAL INVESTMENTS CORPORATION decreased its holdings by 43,959,977 shares, now holding 372,535,027 shares, representing 16.95%[97]. Corporate Governance - The company has not faced any significant media scrutiny or regulatory penalties during the reporting period[65]. - The actual controller and major shareholder of the company, Yuheng International, had their shares judicially frozen due to asset preservation requests from certain stock pledgees[67]. - A total of 12.37 million shares held by Yuheng International were put up for public auction due to debt default, but the auction failed as there were no bids[68]. - The company has no stock incentive plans, employee stock ownership plans, or other employee incentive measures in place during the reporting period[69]. Related Party Transactions - The company reported a daily related party transaction amount of 402.55 million yuan, which is 0.15% of the same type of transactions[71]. - There were no asset or equity acquisition or sale related party transactions during the reporting period[72]. - The company did not engage in any joint external investment related party transactions during the reporting period[73]. - There were no related party debt and credit transactions during the reporting period[74]. - The company has no other significant related party transactions during the reporting period[75]. Guarantees and Commitments - The company has provided guarantees totaling 16.99 million yuan for Yuheng Hong Kong, with a guarantee period of 2 years[80]. - The company has a total of 35 million yuan in guarantees for asset pool business, with a guarantee period of 1 year[80]. - The total approved guarantee amount for subsidiaries during the reporting period was CNY 77,000 million, with actual guarantees amounting to CNY 47,247.14 million[81]. - The total approved guarantee amount at the end of the reporting period was CNY 187,000 million, with actual guarantee balance of CNY 20,994.26 million[81]. Compliance and Accounting - The company’s financial reports are prepared in accordance with the Chinese Accounting Standards, ensuring a true and complete reflection of its financial status[159]. - The company maintains a continuous operating capability for at least 12 months following the reporting period[157]. - The company recognizes cash and cash equivalents as cash on hand and deposits that are readily available for payment[169]. - The company consolidates financial statements based on control, including all subsidiaries under its control in the consolidated financial statements[165].

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2019-053 哈尔滨誉衡药业股份有限公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨誉衡药业股份有限公司（以下简 称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络有限公司共同举 办的"2019 年黑龙江省上市公司投资者网上集体接待日"活动，现将有关事项 公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）参与公司本次投 资者集体接待日活动，时间为 2019 年 6 月 19 日（周三）14:00 至 16:30。 届时公司董事、董事会秘书王禹先生、财务副总监兼总经理助理纪作哲先生 将通过网络在线问答互动的形式，与投资者就公司治理、发展经营情况、融资情 况和可持续发展等投资者关注的问题进行交流。期间，公司高管将全程在线，实 时回答投资者的提问。 欢迎广大投资者积极参与。 特此公告。 哈尔滨誉衡 ...